BPH Management and Insulin Sensitivity

Introduction to BPH and Metabolic Syndrome

The natural history of BPH is progressive, with histopathologic prevalence increasing from >50% at age 60 to 90% by age 85, and metabolic interventions have not been shown to reverse this trajectory 1

Established prostatic enlargement requires specific interventions including alpha-blockers, 5-alpha-reductase inhibitors (which reduce prostate volume by 15-25% after 6 months), or surgical therapies—not metabolic management 2
The American Urological Association recommends treating BPH directly with evidence-based therapies, such as alpha-blockers (alfuzosin, doxazosin, tamsulosin, terazosin) for symptom relief 3
5-alpha-reductase inhibitors (finasteride, dutasteride) are recommended for prostates >30cc to reduce volume and prevent progression, with a strength of evidence supporting their use 4, 2

The American Urological Association recommends monitoring for disease progression using the AUA Symptom Score/IPSS at 6-month intervals 5
PSA levels should be monitored, with adjustments made for 5-alpha-reductase inhibitor use by doubling the value after 1 year, as recommended by clinical guidelines 4, 2
Post-void residual volumes should be monitored, as large PVRs may herald progression, according to the Journal of Urology 6